A Study of LY2405319 in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It
was given as a daily injection under the skin to participants with type 2 diabetes mellitus
(T2DM) for 28 days. This study determined how long the drug stays in the body and how it
affects blood sugar levels. After screening, the study lasted about 2 months for each
participant. Participants continued their prestudy regimen of diet and exercise alone or in
combination with metformin.